Purchase this article with an account.
H.-W. Kwak, E.-S. Kim, S.-W. Lee, S.-Y. Yu; Long-Term Results of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2714.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the long-term clinical efficacy of intravitreal bevacizumab in patients with macular edema (ME) secondary to retinal vein obstruction (RVO).
Sixteen eyes of 16 patients with decreased visual acuity due to ME with RVO were included. Patients received 3 intravitreal injections of 1.25mg (0.05ml) bevacizumab (Avastin®) at intervals of 6 weeks each. All patients completed 1 year of follow-up. The patients underwent additional bevacizumab injection, if ME was increased in optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) with ETDRS chart and macular thickness using OCT were measured at baseline and follow-up visits.
The mean duration of follow-up was 12.4±1.1 months. The mean baseline BCVA (log MAR) was 0.75±0.32 and the final BCVA (log MAR) was 0.42±0.25, a difference that was statistically significant (p<0.05). Mean macular thickness at baseline by OCT was 588.5±301.0µm and decreased to a mean of 191.8±112.0µm at the end of the follow-up (p<0.05). During follow-up, the mean number of injections was 3.31 and there were no systemic side effects observed associated with bevacizumab and no endophthalmitis or other local side effects occurred.
Intravitreal bevacizumab was well tolerated in all patients and effective for improving visual acuity and reducing macular edema for 1 year with 3.31 injections.
This PDF is available to Subscribers Only